My watch list
my.bionity.com  
Login  

Sartorius Supervisory Board appoints two new Executive Board members

10-Dec-2018

Copyright: Sartorius

René Fáber

Copyright: Sartorius

Gerry Mackay

The Supervisory Board of Sartorius AG resolved to make changes in the Executive Board. Effective January 1, 2019, Dr. René Fáber as Head of the Bioprocess Solutions Division and Gerry Mackay as Head of the Lab Products & Services Division will be appointed new members of the company’s Executive Board.

René Fáber, age 43, has been working at Sartorius since 2002. He started as an R&D Scientist in the Membrane Modification Department, then headed R&D Process Technologies. Later, as Vice President, he held various management positions in Marketing for Filtration and Fermentation Technologies, as well as in Key Account Management. In his most recent position before his appointment to the Executive Board, he was responsible for the entire Product Development unit of the Bioprocess Solutions Division. René Fáber studied chemistry in Bratislava, Slovakia, and earned his Ph.D. in polymer chemistry at the Technical University of Munich in Germany. He is of Slovakian nationality.

Gerry Mackay, age 56, joined Sartorius in 2015 from the acquisition of BioOutsource, where he had been its CEO since 2009. Prior to his tenure with BioOutsource, he held international senior level positions in Sales and Marketing at several companies, among them at the U.S. life science company Millipore. At Sartorius, Gerry Mackay as Head of Marketing, Sales and Services of the Lab Products & Services Division drove the momentum of the division‘s new strategic direction towards the biopharmaceutical market and its respective applications and technologies. Gerry Mackay holds a Bachelor’s of Science Honors degree in biochemistry and a Master’s in education, and is of British nationality.

Furthermore, the Supervisory Board and Executive Board member Reinhard Vogt mutually and amicably agreed on the best of terms that the latter will step down from his position on the Executive Board as of December 31, 2018. The Supervisory Board thanks him for his extraordinarily successful service that he has dedicated to the benefit of the company for more than 35 years in various functions, the most recent of which as a member of the Executive Board since 2009. “Mr. Vogt has outstandingly served the company, especially in the strategic alignment and operational leadership of the Bioprocess Solutions Division, which today represents the largest pillar in sales revenue and earnings of the Sartorius Group. We wish Mr. Vogt all the best for the future, in which he will continue to support Sartorius, among other companies, in an advisory capacity,” said Dr. Lothar Kappich, Chairman of the Supervisory Board. “At the same time, we are also pleased to welcome René Fáber and Gerry Mackay, two internationally experienced and successful managers from our own ranks, to join our Executive Board.“

As of January 1, 2019, the Sartorius Executive Board will thus consist of the four following members: Dr. Joachim Kreuzburg (Chairman and CEO); Dr. René Fáber (Head of Bioprocess Solutions), Gerry Mackay (Head of Lab Products & Services); and Rainer Lehmann (Chief Financial Officer).

Facts, background information, dossiers
  • executive board
  • Sartorius
  • appointments
More about Sartorius
  • News

    Sartorius Stedim Biotech and Siemens Sign Long-Term Cooperation Agreement in the Area of Automation

    The Siemens technology group andSartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, have agreed on long-term cooperation in the area of automation. This agreement provides that Sartorius Stedim Biotech will preferably use Siemens automation t ... more

    Sartorius starts off fiscal 2018 successfully

    Sartorius looks back on a successful first quarter 2018. "Both divisions started off the year strongly in line with our expectations and further increased their revenues in the first quarter of 2018 in all regions. On the currency side, however, we faced some headwinds, especially due to th ... more

    Sartorius Stedim supports biotech training at U Penn

    Sartorius Stedim Biotech andPenn State University have entered into a collaborative partnership to advance multidisciplinary teaching and research in biotechnology. This long-term relationship will support the education and preparation of the next generation of biotechnology leaders. Part o ... more

  • Videos

    The New Perfectly Balanced Mechanical Pipette

    Perfectly Balanced – The Tacta Experience Have you ever considered the overall user experience in pipetting? We have. Sartorius proudly presents Tacta, the new premium mechanical pipette with superb comfort and reliability. Tacta makes pipetting effortless and safe, while producing accurate ... more

  • White papers

    Application-specific Membrane Prefilters for Highly Efficient Processes in Biopharmaceutical Production

    New medicines and diagnostics on the one hand and rising cost pressure as a result, for example, of the launch of generics and biosimilars on the other mean that new, highly efficient methods are required in biopharmaceutical production. In order to more

    Filter Integrity Testing

    The integrity testing of sterile filters constitutes a critical and mandatory regulatory step in biopharmaceutical production processes. However, performing such filter integrity tests costs time. Indeed, it can take a good 20 to 30 minutes to perfor more

    Additional Repeatability Test As Part of DKD Calibration

    Together with the customer, Sartorius developed an additional repeatability test, which is now performed as a supplement to DKD calibration. The test enables the measurement uncertainty to be more accurately calculated and, therefore, the quality of more

  • Companies

    Sartorius AG

    The Sartorius Group is a leading international laboratory and process technology provider covering the segments of biotechnology and mechatronics. Founded in 1870, the Goettingen-based company currently employs more than 4,500 persons. The major areas of activity in its biotechnology seg ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE